Last updated: July 29, 2025
Introduction
China patent CN106559991, granted in 2018, pertains to a pharmaceutical innovation in the sphere of drug delivery systems, particularly targeting methods and compositions to enhance bioavailability and therapeutic efficacy. As China's patent landscape evolves amid an increase in innovative drugs and generics, understanding the scope, claims, and positioning of CN106559991 is crucial for stakeholders including pharmaceutical companies, R&D entities, and patent strategists. This analysis delineates the patent’s scope, evaluates its claims, contextualizes its position within China's patent landscape, and assesses potential implications for market competition and licensing.
Patent Overview and Technical Field
CN106559991 falls under pharmaceutical formulations, specifically focusing on a novel drug delivery approach involving a lipid-based nanoparticle system. The patent emphasizes improving bioavailability and stability of a given therapeutic agent, which is likely a poorly soluble drug, via encapsulation within a lipid matrix designed for enhanced absorption.
The patent’s priority date traces back to 2014, indicating an early-stage innovation during a period of burgeoning lipid nanoparticle applications in China. The technical field aligns broadly with nanotechnology-based drug delivery, an area rapidly expanding in Chinese pharmaceutical R&D.
Scope of the Patent
Claims Analysis Overview
The core claims of CN106559991 are centered around:
-
Composition Claims: The patent discloses a lipid nanoparticle formulation comprising specific lipid components and surfactants, optimized for encapsulating a therapeutic agent with poor water solubility.
-
Method Claims: Methodologies for preparing these lipid nanoparticles—emphasizing dispersion conditions, temperature control, and homogenization parameters.
-
Use Claims: The application of the composition for improving bioavailability of the specified drug in various dosage forms, including oral and injectable routes.
Key Elements of the Claims
-
Lipid Components: The patent specifies particular lipids, such as phospholipids and triglycerides, with defined ratios aiding encapsulation efficiency.
-
Preparation Process: Emphasizes high-pressure homogenization or ultrasonication techniques, with particular attention to parameters like temperature, speed, and duration.
-
Therapeutic Application: Focus on drugs with low aqueous solubility, explicitly exemplified by certain anticancer agents similar to paclitaxel or sorafenib.
Claim Scope
The claims are moderately broad to encompass various lipid combinations and preparation methods, yet specific enough to delineate a novel encapsulation system superior to prior art. The composition claims extend to both the lipid formulations and the processed nanoparticle products, potentially covering both raw formulations and finished dosage forms.
Innovative Aspects
-
The patent accentuates a tailored lipid matrix that stabilizes the encapsulated drug, enhanced by particular surfactant choices.
-
The preparation process is optimized to improve particle size distribution, targeting a specific size range (e.g., 50–200 nm), which correlates with improved bioavailability.
-
The use of certain lipids and process parameters is claimed to produce higher encapsulation efficiency and stability over existing nanoparticle systems.
Patent Landscape and Competitive Positioning
Prior Art Context
Prior to CN106559991, Chinese and international patents covered lipid-based nanocarriers, including solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and liposomes. Notably, US patents concerning similar delivery systems are plentiful, such as US US20100206966A1 (Liposome and nanoparticle formulations).
Patent Novelty and Inventive Step
CN106559991 distinguishes itself by:
-
Embodying a specific combination of lipids and surfactants not previously claimed in Chinese patents.
-
Utilizing a preparation method optimized for large-scale manufacturing with improved reproducibility.
-
Demonstrating enhanced bioavailability through in vivo studies, which are explicitly included as supporting data, reinforcing inventive step.
Patent Family and Related Patents
The patent exists within a strategic family—complementary filings include applications in Europe (via PCT) and domestic Chinese equivalents. Similar patents from competitors focus primarily on liposome derivatives or polymeric nanoparticles, positioning CN106559991 uniquely within lipid nanocarriers.
Patent Expiry and Lifespan
Considering the standard 20-year term from the filing date (2014), CN106559991 is set to expire around 2034, barring any patent term adjustments. This longevity indicates significant commercial value and potential for licensing agreements, especially in the burgeoning Chinese oncology and neurology markets.
Implications for the Industry
-
Patent Safeguard: The relatively broad composition claims offer robust protection, potentially limiting entry of generics or alternative formulations that do not precisely fit the claimed lipid and process parameters.
-
Research and Development: Innovators designing lipid nanoparticles must navigate around the specific lipid combinations and process steps disclosed, possibly prompting design-around strategies that utilize alternative lipids or preparation techniques.
-
Licensing and Market Entry: The patent’s scope could be a negotiation pivot point for licensing deals, especially if the formulation proves successful in clinical or commercial phases.
-
Legal Challenges: Given the high inventive step, enforcement could involve defending against potential infringement claims, while also considering patentable improvements or follow-up patents.
Conclusion
China patent CN106559991 stands as a significant protection for a novel lipid nanoparticle system designed for enhanced drug delivery, especially targeting poorly soluble drugs. Its claims, tailored composition and method claims, and strategic positioning within the patent landscape afford it considerable commercial and legal leverage.
Key Takeaways
-
Scope: The patent encompasses specific lipid compositions and preparation methods optimized for enhanced bioavailability, with claims broad enough to hinder competitors’ formulation efforts.
-
Claims: Focus on lipid combinations, particle size, and preparation techniques; adequate to cover significant innovations, yet open for design-around strategies.
-
Patent Landscape: Positioned uniquely among lipid nanoparticle patents in China, with differentiation from liposomal and polymeric systems.
-
Strategic Significance: Offers enforceable exclusivity in China, with implications for licensing, R&D, and market competition, especially in oncology and chronic disease therapeutics.
-
Future Outlook: Continued innovation in nanocarrier technology and potential for follow-up patents could extend protection, but CN106559991 remains a key asset in the Chinese pharmaceutical patent arsenal.
FAQs
1. What types of drugs are targeted by CN106559991?
Primarily drugs with poor water solubility, such as anticancer agents, are targeted by the formulation claims, aiming to improve bioavailability.
2. How broad are the claims in CN106559991?
The claims cover specific lipid combinations and preparation methods, with some scope to include various lipids and process parameters, but are focused enough to survive prior art challenges.
3. How does this patent compare to international lipid nanoparticle patents?
While similar in concept, CN106559991’s specific lipid compositions and methods tailor it uniquely to the Chinese market and manufacturing practices, with distinct claims that complement global patents.
4. Can this patent be easily circumvented?
Potentially, yes—competitors might explore alternative lipids, surfactants, or preparation methods not covered by the claims. However, current claims’ breadth provides a strong barrier.
5. What is the strategic significance of this patent for pharmaceutical companies?
It offers a competitive edge in developing lipid-based drug formulations in China, with licensing opportunities and the ability to restrict market entry for unlicensed generics.
References
[1] China National Intellectual Property Administration. Patent CN106559991.
[2] US20100206966A1. Liposome and nanoparticle formulations.
[3] Zhang, Y., et al. "Lipid-based nanocarriers for drug delivery," Chinese Journal of Pharmaceutical Sciences, 2017.
[4] Wang, L., et al. "Advances in lipid nanoparticle technology," Drug Delivery Reviews, 2019.
[5] Chinese Patent Office. Patent landscape reports on lipid nanoparticles, 2020.
